Scott Hauenstein

2.0k total citations
39 papers, 1.7k citations indexed

About

Scott Hauenstein is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Scott Hauenstein has authored 39 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Genetics, 21 papers in Epidemiology and 18 papers in Immunology. Recurrent topics in Scott Hauenstein's work include Inflammatory Bowel Disease (26 papers), Microscopic Colitis (20 papers) and Immunodeficiency and Autoimmune Disorders (14 papers). Scott Hauenstein is often cited by papers focused on Inflammatory Bowel Disease (26 papers), Microscopic Colitis (20 papers) and Immunodeficiency and Autoimmune Disorders (14 papers). Scott Hauenstein collaborates with scholars based in United States, Belgium and Canada. Scott Hauenstein's co-authors include Sharat Singh, Linda Ohrmund, Séverine Vermeire, Niels Vande Casteele, Ann Gils, Paul Rutgeerts, Steven Lockton, John J. Perona, Ya‐Ming Hou and S. Lockton and has published in prestigious journals such as Journal of Biological Chemistry, Gastroenterology and PLoS ONE.

In The Last Decade

Scott Hauenstein

38 papers receiving 1.6k citations

Peers

Scott Hauenstein
Cathérine Reenaers Belgium
Matthias Jürgens Germany
Nobuhito Kashiwagi Japan
Alison Innes United States
S Targan United States
Beena Gulwani-Akolkar United States
M. Bunce United Kingdom
Srdjan Pašić Serbia
A. Balas Spain
Atar Lev Israel
Cathérine Reenaers Belgium
Scott Hauenstein
Citations per year, relative to Scott Hauenstein Scott Hauenstein (= 1×) peers Cathérine Reenaers

Countries citing papers authored by Scott Hauenstein

Since Specialization
Citations

This map shows the geographic impact of Scott Hauenstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Hauenstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Hauenstein more than expected).

Fields of papers citing papers by Scott Hauenstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Hauenstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Hauenstein. The network helps show where Scott Hauenstein may publish in the future.

Co-authorship network of co-authors of Scott Hauenstein

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Hauenstein. A scholar is included among the top collaborators of Scott Hauenstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Hauenstein. Scott Hauenstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yarur, Andrés, Anjali Jain, Scott Hauenstein, et al.. (2016). Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohnʼs Disease and Ulcerative Colitis. Inflammatory Bowel Diseases. 22(2). 409–415. 83 indexed citations
3.
Papamichael, Konstantinos, Karolien Claes, Magali de Bruyn, et al.. (2015). Serology panel for prediction relapse after discontinuation of infliximab in patients with Crohn's disease achieving clinical remission. 9. 1 indexed citations
4.
Yarur, Andrés, Frank Czul, Daniel A. Sussman, et al.. (2015). Concentrations of 6-Thioguanine Nucleotide Correlate With Trough Levels of Infliximab in Patients With Inflammatory Bowel Disease on Combination Therapy. Clinical Gastroenterology and Hepatology. 13(6). 1118–1124.e3. 121 indexed citations
5.
Baert, Filip, Venkateswarlu Kondragunta, Steven Lockton, et al.. (2015). Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. Gut. 65(7). 1126–1131. 81 indexed citations
6.
Zitomersky, Naamah, Paul D. Mitchell, Scott Hauenstein, et al.. (2015). Antibodies to Infliximab Are Associated with Lower Infliximab Levels and Increased Likelihood of Surgery in Pediatric IBD. Inflammatory Bowel Diseases. 21(2). 307–314. 40 indexed citations
7.
Casteele, Niels Vande, Reena Khanna, Barrett G. Levesque, et al.. (2014). The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut. 64(10). 1539–1545. 224 indexed citations
8.
Yarur, Andrés, Katherine Drake, Scott Hauenstein, et al.. (2014). 788 Higher 6-Thioguanine Nucleotide Concentrations Are Associated With Higher Trough Levels of Infliximab in Patients on Combination Therapy. Gastroenterology. 146(5). S–134. 3 indexed citations
9.
Papamichael, Konstantinos, Niels Vande Casteele, Ann Gils, et al.. (2014). Long-Term Outcome of Patients With Crohn’s Disease Who Discontinued Infliximab Therapy Upon Clinical Remission. Clinical Gastroenterology and Hepatology. 13(6). 1103–1110. 63 indexed citations
10.
Baert, Filip, David Drobne, Ann Gils, et al.. (2014). Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy. Clinical Gastroenterology and Hepatology. 12(9). 1474–1481.e2. 99 indexed citations
11.
Casteele, Niels Vande, Ann Gils, Sharat Singh, et al.. (2013). Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient. The American Journal of Gastroenterology. 108(6). 962–971. 280 indexed citations
12.
Hauenstein, Scott, Linda Ohrmund, Reshma Shringarpure, et al.. (2013). Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. Journal of Pharmaceutical and Biomedical Analysis. 78-79. 39–44. 74 indexed citations
13.
Wolf, Douglas C., Scott Hauenstein, Steven Lockton, & Sharat Singh. (2013). Tu1148 Mechanisms of Loss of Response to Adalimumab in Crohn's Disease. Gastroenterology. 144(5). S–775. 4 indexed citations
14.
Velayos, Fernando, Sarah Sheibani, Steven Lockton, et al.. (2013). 490 Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between Ata and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients. Gastroenterology. 144(5). S–91. 26 indexed citations
15.
Hauenstein, Scott, Linda Ohrmund, Emil Chuang, et al.. (2012). P253 Transient versus sustained antibodies to infliximab: Possibility to overcome low titer antibody responses by dose optimisation. Journal of Crohn s and Colitis. 6. S110–S110. 4 indexed citations
16.
Ohrmund, Linda, Scott Hauenstein, Jared Salbato, et al.. (2012). Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. Journal of Immunological Methods. 382(1-2). 177–188. 175 indexed citations
17.
Feagan, Brian G., Sharat Singh, Steven Lockton, et al.. (2012). 565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD). Gastroenterology. 142(5). S–114. 36 indexed citations
18.
Hauenstein, Scott, Ya‐Ming Hou, & John J. Perona. (2008). The Homotetrameric Phosphoseryl-tRNA Synthetase from Methanosarcina mazei Exhibits Half-of-the-sites Activity. Journal of Biological Chemistry. 283(32). 21997–22006. 37 indexed citations
19.
Liu, Cuiping, et al.. (2007). Kinetic Quality Control of Anticodon Recognition by a Eukaryotic Aminoacyl-tRNA Synthetase. Journal of Molecular Biology. 367(4). 1063–1078. 25 indexed citations
20.
Hauenstein, Scott, Chunmei Zhang, Ya‐Ming Hou, & John J. Perona. (2004). Shape-selective RNA recognition by cysteinyl-tRNA synthetase. Nature Structural & Molecular Biology. 11(11). 1134–1141. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cathérine Reenaers Breakdown of academic impact, for papers by Matthias Jürgens Breakdown of academic impact, for papers by Nobuhito Kashiwagi Breakdown of academic impact, for papers by Alison Innes Breakdown of academic impact, for papers by S Targan Breakdown of academic impact, for papers by Beena Gulwani-Akolkar Breakdown of academic impact, for papers by M. Bunce Breakdown of academic impact, for papers by Srdjan Pašić Breakdown of academic impact, for papers by A. Balas Breakdown of academic impact, for papers by Atar Lev
Rankless by CCL
2026